Effect of anti-IgE antibody on immune system responses and short-term outcome in acute asthma in children

点击翻译按钮获取中文摘要

We plan to undertake a randomised, double-blind, placebo-controlled, clinical trial of anti-IgE antibody given at the time of an acute attack of asthma in children aged 6-12 years. The idea for this arose from our own novel data – IgE levels increase with the most common infection causing acute asthma. Given evidence the virus uses IgE to cause inflammation, giving anti-IgE during the attack should reduce the severity of the attack and produce a new, effective treatment for acute asthma.